Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $11.30 and last traded at $11.47, with a volume of 486380 shares traded. The stock had previously closed at $10.67.
Wall Street Analyst Weigh In
Several analysts recently issued reports on MNMD shares. Chardan Capital reaffirmed a "buy" rating and issued a $20.00 price target on shares of Mind Medicine (MindMed) in a report on Friday, August 1st. Oppenheimer started coverage on shares of Mind Medicine (MindMed) in a report on Monday, August 4th. They issued an "outperform" rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $26.50.
Read Our Latest Report on MNMD
Mind Medicine (MindMed) Stock Up 8.6%
The company has a market capitalization of $881.96 million, a price-to-earnings ratio of -7.57 and a beta of 2.49. The stock's fifty day simple moving average is $9.59 and its two-hundred day simple moving average is $7.73. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.98 and a quick ratio of 4.98.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.12). On average, sell-side analysts predict that Mind Medicine will post -1.35 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Mark Sullivan sold 11,278 shares of the stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $9.77, for a total value of $110,186.06. Following the sale, the insider owned 293,852 shares of the company's stock, valued at $2,870,934.04. This trade represents a 3.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Karlin sold 7,704 shares of the stock in a transaction dated Thursday, September 25th. The stock was sold at an average price of $9.77, for a total transaction of $75,268.08. Following the completion of the sale, the insider directly owned 430,625 shares in the company, valued at approximately $4,207,206.25. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,779 shares of company stock valued at $437,491. Company insiders own 2.26% of the company's stock.
Institutional Trading of Mind Medicine (MindMed)
A number of large investors have recently modified their holdings of MNMD. Ameriprise Financial Inc. acquired a new stake in shares of Mind Medicine (MindMed) in the 4th quarter worth about $88,000. BNP Paribas Financial Markets acquired a new position in Mind Medicine (MindMed) during the 4th quarter valued at about $74,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mind Medicine (MindMed) by 15.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 45,690 shares of the company's stock valued at $318,000 after buying an additional 6,182 shares during the period. Millennium Management LLC increased its stake in Mind Medicine (MindMed) by 134.5% during the 4th quarter. Millennium Management LLC now owns 185,721 shares of the company's stock valued at $1,293,000 after buying an additional 106,511 shares during the period. Finally, Nuveen Asset Management LLC increased its stake in Mind Medicine (MindMed) by 3.2% during the 4th quarter. Nuveen Asset Management LLC now owns 286,334 shares of the company's stock valued at $1,993,000 after buying an additional 8,856 shares during the period. Institutional investors and hedge funds own 27.91% of the company's stock.
Mind Medicine (MindMed) Company Profile
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
